GlassScriptPhysician profile
Roxanne M Murphy
NPI 1376128579
$1,993.25
in general payments reported to CMS, 2019-2025
12 companies · $694 in 2025
The $694 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $54.79 · 2023: $284 · 2024: $961 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $631.73 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $312.86 | 2023-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $233.98 | 2024-2025 | |
| Grifols USA, LLC | $231.29 | 2022-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $225.96 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.23 | 2022-2025 | Ofev, Stiolto Respimat |
| Inspire Medical Systems, INC. | $72.02 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $55.04 | 2023-2025 | Dificid, Recarbrio, Zerbaxa |
| Getinge USA Sales, LLC | $25.68 | 2025 | Vasoview Hemopro 2 |
| Intuitive Surgical, INC. | $24.49 | 2025 | |
| Abbvie INC. | $23.72 | 2023 | |
| Axsome Therapeutics, INC. | $21.25 | 2024 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.